The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells

Blood

Volumn 109, Issue 10, 2007, Pages 4470-4477

  Colla, Simona ^a   Zhan, Fenghuang ^a   Xiong, Wei ^a   Wu, Xiaosong ^a   Xu, Hongwei ^a   Stephens, Owen ^a   Yaccoby, Shmuel ^a   Epstein, Joshua ^a   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; LENALIDOMIDE; PROTEIN DKK1; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL INTERACTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OXIDATIVE STRESS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 34248394360     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-056747     Document Type: Article

References (51)

1. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J. 2003;4:310-314.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
4. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32:290-292.
5. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108:3392-3396.
6. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11:3286-3305.
7. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone disease. Gene. 2004;341:19-39.
8. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209.
9. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
10. Shaughnessy JD Jr, Barlogie B. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev. 2003;194:140-163.
11. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106:3160-3165.
12. Yaccoby S, Ling W, Zhan F, Walker F, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106-2111.
13. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028.
14. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene. 2004;23:8520-8526.
15. Gonzalez-Sancho JM, Aguilera O, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is down-regulated in human colon cancer. Oncogene. 2005;24:1098-1103.
16. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J. 2005;24:73-84.
17. Wang J, Shou J, Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene. 2000;19:1843-1848.
18. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene. 2002;21:878-889.
19. Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;26:6021-6027.
20. Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression Profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol. 2006;126:2490-2506.
21. Grotewold L, Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J. 2002;21:966-975.
22. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999;21:326-329.
23. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A. 1998;18:10541-10546.
24. Hu MC, Qiu WR, Wang YP. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene. 1997;19:2277-2287.
25. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003;54:8797-8801.
26. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 2006;97:540-545.
27. Anderson KC. Lenalidomide and thalidomide: mechanisms of action: similarities and differences. Semin Hematol. 2005;42:S3-8.
28. Chauhan D, Li G, Hideshima T, Podar K, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;20:17593-17596.
29. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
30. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
31. Adler V, Schaffer A, Kim J, Dolan L, Ronai Z. UV irradiation and heat shock mediate JNK activation via alternate pathways. J Biol Chem. 1995;44:26071-26077.
32. Shen HM, Liu ZG. JNK signaling is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med. 2006;40:928-939.
33. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64:2016-2023.
34. Zufferey R, Nagy D, Mendel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871-875.
35. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633-2638.
36. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006; 7:849-858.
37. Parman T, Wiley Mj, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999;5:582-585.
38. Hitomi J, Katayama Y, Eguchi T, et al. Involvement of caspase-4 in endoplasmic-reticulum-specific apoptosis and amyloid-β-induced cell death. J Cell Biol. 2004;165:347-356.
39. Tan Y, Dourdin N, Wu C, et al. Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2006;281:16016-16024.
40. Tsuji M, Inanami O, Kuwabara M. Neuroprotective effect of alpha-phenyl-N-tert-butylnitrone in gerbil hippocampus is mediated by the mitogen-activated protein kinase pathway and heat shock proteins. Neurosci Lett. 2000;282:41-44.
41. Ahmed S, Rahman A, Hasnain A, Glodberg VM, Haqqi TM. Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1. J Pharmacol Exp Ther. 2003;305:981-988.
42. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of Dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;21:259-264.
43. Bratton SB, Cohen GM. Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci. 2001;22:306-315.
44. Cappuccio I, Calderone A, Busceti C, et al. Induction of DKK1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci. 2005;25:2647-2657.
45. Lee AY, He B, You Liang, et al. DKK1 antagonizes Wnt signaling independent of β-catenin in human mesothelioma. Biochem Biophys Res Commun. 2004;323:1246-1250.
46. Mikheev AM, Mikheeva SA, Binrong L, Cohen P, Zarbl H. A functional genomics approach for the identification of putative tumor suppressor gene: DKK1 as suppressor of HeLa cell transformation. Carcinogenesis. 2004;25:47-59.
47. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DKK1 gene in human colorectal cancer. Oncogene. 2006;15:1-6.
48. Peng S, Chenglin M, Li J, Fan X, Cao Y, Duan E. DKK1 induced apoptosis in human placental choriocarcinoma is independent of canonical Wnt signaling. Biochem Biophys Res Commun. 2006;350:641-647.
49. Qiang YW, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005;106:1786-1793.
50. Kuphal S, Lodermaeyer S, Bataille F, Schuierer M, Hoang BH, Bosserhoff AK. Expression of DKK genes is strongly reduced in malignant melanoma. Oncogene. 2006;3:1-10.
51. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;16:6122-6127.